Photo Credit: blueringmedia
The following is a summary of “CD1a affects the recurrence and prognosis of ovarian cancer,” published in the November 2024 issue of Obstetrics and Gynecology by Zhu et al.
Ovarian cancer (OV) is a leading cause of death among gynecologic cancers, with high recurrence rates affecting patient survival, CD1a is a molecule implicated in immune response modulation and may influence cancer outcomes.
Researchers conducted a retrospective study to explore the correlation between CD1a expression and recurrence or prognosis in OV.
They analyzed CD1a expression profiles in OV, recurrent OV, and normal tissues using data from The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), Gene Expression Omnibus (GEO), and Genotype-Tissue Expression (GTEx) databases. Immunohistochemical detection was also used to assess CD1a expression in normal and cancerous tissues. Survival analysis was conducted using Kaplan–Meier curves to estimate HR, with immune cell correlations assessed from TCGA data (P<0.05).
The results showed that CD1a expression was higher in OV compared to normal tissues (P<0.05) but significantly lower in recurrent OV (TCGA-OV, P<0.0001; ICGC-OV, P<0.0001). Patients with higher CD1a expression had better survival outcomes (HR [low], 1.426; 95% CI, 0.912–2.128; P=0.050), with improved prognosis in both OV (P=0.004, HR [low] = 2.462; 95% CI [1.346–4.504]) and recurrent OV (P=0.011, HR [low] = 2.199; 95% CI [1.202–4.024]). Additionally, CD1a was strongly correlated with immune cells, including CD8+ T cells (P=2.65e−6), macrophages (P=7.52e−13), and natural killer cells (P=8.28e−12).
They concluded that CD1a expression influenced recurrence and survival in OV, potentially through the interaction with immune cells.
Source: obgyn.onlinelibrary.wiley.com/doi/10.1111/jog.16120
